LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.

Early August, 2025, 19 of the 30 Dow Index were tagged "safer" for dividends as they showed positive one-year returns and ...

Key Points Non-GAAP earnings per share (EPS) of $2.25 in Q2 2025 far surpassed the analyst estimate of $0.32 and rose 923% year-over-year compared to Q2 2024 (non-GAAP adjusted diluted EPS per ADS).

Amgen beat Q2 earnings and revenue expectations, raised 2025 guidance, and reported strong product sales growth across key ...

Adma Biologics Inc. ADMA) on Wednesday reported second-quarter net income of $34.2 million. On a per-share basis, the Ramsey, ...

With autonomy from its former parent, we think Sandoz can freely allocate resources to fit its best needs and grow the business. Sandoz is one of the largest biosimilars players in the world, and we ...

Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Major indices were in the green early on Thursday after Donald Trump's newly announced chip tariffs included broad exemptions.

Major indices delivered solid gains on Wednesday as market participants thumbed over a fresh batch of corporate earnings.

Eli Lilly stock tumbled Thursday on an unexpected setback for its obesity franchise, sending shares of its rival flying.